Focus on microalbuminuria to improve cardiac and renal protection

Nephron - Clinical Practice

Volumn 111, Issue 3, 2009, Pages

  De Jong, Paul E ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; Estimated glomerular filtration rate; Microalbuminuria; Screening

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION TEST; MICROALBUMINURIA; PRIORITY JOURNAL; PROGNOSIS; RENAL PROTECTION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ALBUMINURIA; CARDIOVASCULAR DISEASES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; RISK FACTORS;

EID: 59749103809     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201568     Document Type: Review

References (43)

1. Gansevoort RT, van der Heij B, Stegeman CA, de Charro FT, Nieuwenhuizen MG, de Zeeuw D, de Jong PE: Trends in the incidence of treated end-stage renal failure in the Netherlands:hope for the future? Kidney Int Suppl 2004;92:S7-S10.
2. Glassock RJ, Winnearls C: An epidemic of chronic kidney disease: fact or fiction? Nephron Dial Transplant 2008;23:1117-1121.
3. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989;32:219-226.
4. Stehouwer CDA, Fischer HRA, van Kuijk AWR, Polak BC, Donker AJ: Endothelial dysfunction precedes the development of microalbuminuria in insulin-dependent diabetes mellitus. Diabetes 1995;44:561-564.
5. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G: Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994;344:14-18.
6. Gibb DM, Tomlinson PA, Dalton NR, Turner C, Shah V, Barratt TM: Renal tubular proteinuria and microalbuminuria in diabetic patients. Arch Dis Child 1989;64:129-134.
7. Osicka TM, Houlihan CA, Chan JG, Jerums G, Comper WD: Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000;49:1579-1584.
8. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
9. Webb DJ, Newman DJ, Chaturvedi N, Fuller JH: The use of the Micral-Test strip to identify the presence of microalbuminuria in people with insulin dependent diabetes mellitus participating in the EUCLID study. Diabetes Res Clin Pract 1996;31:93-102.
10. Lambers Heerspink HJ, Witte EC, Bakker SJ, de Jong PE, de Zeeuw D, Gansevoort RT: Screening and monitoring for albuminuria: the performance of the HemoCue point-ofcare system. Kidney Int 2008;74:377-383.
11. Witte EC, Lambers Heerspink HJ, Bakker SJL, de Jong PE, de Zeeuw D, Gansevoort RT: First morning voids or spot urine samples for determination of microalbuminuria? J Am Soc Nephrol 2008 (in press).
12. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE: The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005;94:S28-S35.
13. Jafar TH, Chaturvedi N, Hatcher J, Levey AS: Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant 2007;22:2194-2200.
14. Gansevoort RT, Brinkman JW, Bakker SJL, de Jong PE, de Zeeuw D: Evaluation of measures of urinary albumin excretion in epidemiologic studies. Am J Epidemiol 2006;164:725-727.
15. Brinkman JW, de Zeeuw D, Duker JJ, Gansevoort RT, Kema IP, de Jong PE, Bakker SJL: Prolonged frozen storage of urine reduces the predictive value of albuminuria for mortality. Clin Chem 2007;53:153-154.
16. De Jong PE, Brenner BM: From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004;66:2109-2118.
17. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285-2293.
18. Brantsma AH, Atthobari J, Bakker SJL, de Zeeuw D, de Jong PE, Gansevoort RT: What predicts progression and regression of urinary albumin excretion in the non-diabetic population. J Am Soc Nephrol 2007;18:637-645.
19. Bello AK, de Zeeuw D, El Nahas ME, Brantsma AH, Bakker SJL, de Jong PE, Gansevoort RT: Impact of weight change on albuminuria in the general population. Nephrol Dial Transpl 2007;22:1619-1627.
20. Wachtell E, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, et al: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-906.
21. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300.
22. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans ROB, Janssen WM, Grobbee DE, de Jong PE: Urinary albumin excretion predicts cardiovascular mortality in the general population. Circulation 2002;106:1777-1782.
23. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
24. Tonelli M, Jose P, Curhan G, et al: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. Br Med J 2006;332:1426-1431.
25. Foster MC, Hwang S-J, Larson MG: Crossclassification of microalbuminuria and reduced glomerular filtration rate. Arch Intern Med 2007;167:1386-1392.
26. Brantsma AH, Bakker SJL, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT: Cardiovascular and renal outcome in subjects with K/DOQI stages 1-3 chronic kidney disease; the importance of urinary albumin excretion. Nephrol Dial Transplant 2008 (in press).
27. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639.
28. Cao JJ, Biggs ML, Barzilay J, Konen J, Psaty BM, Kuller L, Bleyer AJ, Olson J, Wexler J, Summerson J, Cushman M: Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the Cardiovascular Health Study. Atherosclerosis 2008;197:806-813.
29. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005;112:969-975.
30. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacuer D, Ducimetiere P, et al: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
31. Asselbergs FW, Diercks GFH, Hillege HL, van Boven AJ, Janssen WMT, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular End-Stage Disease Intervention Trial (PREVEND IT) Investigators: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-2816.
32. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, de Zeeuw D, de Jong PE: An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004;92:S18-S21.
33. Ishani A, Granditis GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD: Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006;17:1444-1452.
34. De Jong PE, Gansevoort RT, Bakker SJL: Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength? J Nephrol 2007;20:375-380.
35. De Jong PE, van der Velde M, Gansevoort RT, Zocalli C: Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 2008;3:616-623.
36. Parving HH, Lehnert H, Brochner-Mortensen J: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
37. Iseki K, Kinjo K, Iseki C, Takishita S: Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004;44:806-814.
38. Viktorsdottir O, Palsson R, Andresdottir MB, Aspelund T, Gudnason V, Indridason OS: Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant 2005;20:1799-1807.
39. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, van Gilst WH, de Zeeuw D, de Jong PE: Microalbuminuria is common, also in a non-diabetic, non-hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001;249:519-526.
40. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States. JAMA 2003;290:199-206.
41. Van der Velde M, de Jong PE, Gansevoort RT: Comparison of screening approaches for chronic kidney disease. J Am Soc Nephrol 2008; 19, ASN Abstract Issue (in press).
42. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR: Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003;290:3101-3114.
43. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LTW, Postma MJ, for the PREVEND IT Study Group: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study and the Prevention of Renal and Vascular end-Stage Disease Intervention Trail (PREVEND IT). Clin Ther 2006;28:432-444.